Hussman Strategic Advisors’s Impax Laboratories, Inc. IPXL Stock Holding History

Hussman Strategic Advisors’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-200,000	Closed	-$3.89M	–	261
2018 Q1	$3.89M	Buy	200,000 +100,000	+100%	+$1.96M	1.08%	16
2017 Q4	$1.67M	Buy	+100,000	New	+$1.83M	0.48%	89
2015 Q4	–	Sell	-150,000	Closed	-$5.28M	–	260
2015 Q3	$5.28M	Sell	150,000 -50,000	-25%	-$2.25M	0.67%	62
2015 Q2	$9.18M	Sell	200,000 -50,000	-20%	-$2.37M	1.06%	31
2015 Q1	$11.7M	Hold	250,000	–	–	1.23%	25
2014 Q4	$7.92M	Hold	250,000	–	–	0.79%	47
2014 Q3	$5.93M	Sell	250,000 -60,000	-19%	-$1.54M	0.51%	85
2014 Q2	$9.3M	Buy	310,000 +90,000	+41%	+$2.43M	0.71%	61
2014 Q1	$5.81M	Buy	+220,000	New	+$5.5M	0.44%	90

Hussman Strategic Advisors's IPXL Position: Q2 2018 in Review

Hussman Strategic Advisors sold out of Impax Laboratories, Inc. (IPXL) in Q2 2018, closing a stake of 200,000 shares — an estimated $3.89M sold.

Hussman Strategic Advisors first reported a position in IPXL in Q1 2014 and held it in 9 quarters. The position peaked at $11.7M in Q1 2015. 1 fund tracked by Wall St. Rank holds IPXL as of Q2 2018.

Hussman Strategic Advisors reported no remaining Impax Laboratories, Inc. position as of Q2 2018 after selling out during the quarter.
Hussman Strategic Advisors sold 200,000 Impax Laboratories, Inc. shares in Q2 2018, an estimated $3.89M.
Hussman Strategic Advisors first reported a position in Impax Laboratories, Inc. in Q1 2014 and held it in 9 quarters.
Hussman Strategic Advisors's Impax Laboratories, Inc. position peaked at $11.7M in Q1 2015.
1 fund tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2018.

Based on Hussman Strategic Advisors's 13F filing for Q2 2018, filed 31 Jul 2018.